Abstract Several agents used for treatment of colon and other cancers induce reactive oxygen species (ROS), and this plays an important role in their anticancer activities. In addition to the well-known proapoptotic effects of ROS inducers, these compounds also decrease expression of specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4 and several prooncogenic Sp-regulated genes important for cancer cell proliferation, survival, and metastasis. The mechanism of these responses involves ROS-dependent downregulation of miR-27a or miR-20a (and paralogs) and induction of two Sp repressors, ZBTB10 and ZBTB4, respectively. This pathway significantly contributes to the anticancer activity of ROS inducers and should be considered in the development of drug combinations for cancer chemotherapy.
Introduction
Colorectal cancer is the third most diagnosed cancer in men and the second most frequently observed cancer in women worldwide [1] [2] [3] . Over one million new cases of colon cancer were diagnosed in 2008, and it is estimated that the annual number of deaths due to colorectal cancer is more than half a million. This accounts for 8 % of all cancer deaths, making it the fourth leading cause of mortality from cancer. Colon cancer incidence is higher in the more developed countries, with 0.7 million cases in 2008, than in the less developed nations, with 0.5 million cases in 2008 [1] . Although the prevalence rates for colorectal cancer are higher in individuals from developed and industrialized nations, Western lifestyles in less developed countries are resulting in increasing incidence rates [4] . Individuals from underdeveloped countries who migrate to an industrialized country with a high incidence of colon cancer eventually exhibit the higher incidence rates [5] .
Risk factors for colon cancer include obesity, increased alcohol intake, smoking, increased consumption of red meat, processed meats, highly refined grains, and starch, and low intakes of fruits and vegetables. The risks for colon cancer are decreased with increasing consumption of white meat, such as poultry and fish, and plant-based food sources of protein, substitution of saturated with unsaturated fats, and incorporating legumes, sugars, and unrefined grains as the major source of carbohydrates [6, 7] . A recent large case-control study demonstrated a strong correlation between a diet rich in fruit and vegetables and reduced risk of colorectal cancers. According to the study, the total antioxidant capacity from different food sources rather than the levels of their individual antioxidants is considered to be critical for decreasing colorectal cancer risk [8] . Western diets, which comprise large portions of red meat with high levels of iron stores, are thought to be a cancer risk factor. Heme iron is present in significant quantities in red meat and promotes growth of transformed cells and increases DNA damage by acting as a prooxidant and generating oxidative stress in cells [9, 10] . processes in the cell [11•, 12] . It has been established that cancer cells thrive under some levels of oxidative stress, and compared with noncancer tissue, ROS levels are elevated in breast, colon, pancreatic, prostate, and other cancers [13] [14] [15] . In addition, oxidative DNA damage by ROS contributes to carcinogenesis by causing mutations in the genetic material. ROS can cause single-strand breaks and genetic instability, and this is due to oxidation of purines and pyrimidines and generation of alkali-labile sites. Oxidative damage that commonly leads to mutations is associated with modification of GC base pairs, and these mutations are primarily due to basepair substitution and less frequently deletions and insertions [16] . Furthermore, ROS play a crucial role in regulating expression of genes associated with cancer cell growth and survival, angiogenesis, invasion, and metastasis by activating transcription factors, including nuclear factor κB, activator protein 1, and hypoxia inducible factor 1α [17] .
In addition to facilitating tumor growth and survival, ROS also play a role as an important inhibitor of cancer cell proliferation and in induction of apoptosis. Excessive production of ROS in cancer cells induces apoptosis or autophagy and in some cases necrosis by damaging cellular components such as DNA, protein, and lipid membranes [17] . Disruption of the mitochondrial membrane integrity can result in release of cytochrome c , which in turn activates the intrinsic apoptotic machinery [18] . Similarly, Fas ligand, an upstream activator of the extrinsic apoptotic pathway, mediates induction of ROS, which is essential for initiating the apoptotic signaling cascade [19] . ROS also have an important function in autophagic cell death in many cancer types, including colon, pancreatic, breast, glioma, glioblastoma, and non-small-cell lung cancer [20] [21] [22] [23] [24] . In addition to programmed cell death, necrotic cell death is observed in cancer cells when the levels of ROS exceed those necessary for inducing apoptosis and autophagy, and this has been reported in multiple myeloma, prostate cancer, hepatoma, and leukemia cells [25] [26] [27] [28] .
ROS and Cancer Therapy
The phenomenon of drug-induced ROS in mediating induction of apoptosis has been extensively exploited to design effective strategies for cancer chemotherapy. Several studies investigating the effects of both natural and synthetic anticancer agents in colorectal cancers have shown that many of these compounds induce ROS, and although not always recognized, this pathway may be the predominant mechanism of action for several drugs used in cancer chemotherapy. The effects of antioxidants in attenuating the responses of various chemotherapeutic drugs provide critical evidence for the role of ROS in mediating their activites.
Recent Reports of ROS-Inducing Anticancer Agents (Table 1) The anticarcinogenic properties of curcumin, the active ingredient of the Indian spice turmeric, have been extensively investigated, and its role in ROS-dependent growth inhibition has been reported in several studies. A structural analogue of curcumin, dehydrozingerone, extracted from ginger (Zingiber officinale) was recently shown to induce intracellular ROS and induce cell cycle arrest at G 2 /M phase in HT-29, HCT-116, and HCT-15 colon cancer cells. Cotreatment with the ROS scavenger N -acetyl-L -cysteine repressed dehydrozingeronemediated cell cycle arrest at G 2 /M phase in HT-29 cells. However, other antioxidants did not reverse the effects of dehydrozingerone on cell cycle arrest. The authors of the study indicated that further studies are required to confirm the involvement of ROS, since dehydrozingerone is structurally similar to curcumin and could conjugate with glutathione, the direct metabolite of N-acetyl-L-cysteine, to reduce its potency in the cell [29] . A study on the anticancer effects of curcuminoids in both HT-29 and SW480 colon cancer cells and CCD18Co colon fibroblasts reported inhibition of HT-29 and SW480 colon cancer cell growth and enhanced activity of the chemotherapeutic agent 5-fluorouracil. These effects were due to a decrease in the levels of multidrug resistance protein 1 (MDR1) and ROS-mediated repression of specificity protein (Sp) transcription factors which regulate MDR1, and this will be discussed in detail later in the review [30] . Another study showed that curcumin inhibited HCT-15 colon cancer cell proliferation and induced apoptosis, and this was accompanied by generation of ROS. Furthermore, treatment of HCT-15 colon cancer cells with curcumin in this study decreased the levels of precursor messenger RNA (mRNA) processing factor 4B and mutated forms of p53 [31] .
The active ingredients of grape seed extract (GSE) such as epigallocatechins and procyanidins also inhibit growth of tumors derived from various cancer types and are cytoprotective to normal human gastric mucosal cells. GSE induced apoptosis and an increase in ROS and Ca 2+ levels in Caco-2 colon cancer cells, and this was accompanied by inactivation of extracellular-signal-regulated kinase. Cotreatment of Caco-2 cells with the antioxidant N-acetyl-Lcysteine and the calcium chelator ethylene glycol tetraacetic acid suppressed GSE-induced apoptosis and inactivation of extracellular-signal-regulated kinase, indicating a critical role of ROS in the anticarcinogenic activity of GSE [32] . Another study demonstrated a synergistic effect between (−)-epigallocatechin-3-gallate, vitexin-2-O -xyloside, and raphasatin (4-methylsulfanyl-3-butenyl isothiocyanates) on growth inhibition in LoVo and CaCo-2 colon cancer cells. These responses were accompanied by increased levels of ROS, G 0 /G 1 phase cell cycle arrest, and induction of apoptosis by modulation of Bax, Bcl-2 and caspase 9 suggestive of ROS-dependent mitochondrial activation of apoptosis [33] . Similarly, hirsutanol A, a sesquiterpene compound extracted from fungal Chondrostereum sp., caused accumulation of ROS in SW620 colon cancer cells, altering the mitochondrial membrane potential (MMP), followed by release of cytochrome c and induction of apoptosis; these responses were blocked by addition of the ROS scavenger N-acetyl-L-cysteine. In addition, results from this study indicate that generation of ROS caused by hirsutanol A was independent of the mitochondrial respiratory chain in SW620 colon cancer cells [34] .
Fatty acid derivatives such as dietary conjugated linoleic acids and 5-hydroxy-6-iodo-8,11,14-eicosatrienoic δ-lactone (IL-δ), an iodinated arachidonic acid derivative, induced apoptosis in SW480 and HCT116 and HT29 colon cancer cells, respectively. Trans-10, cis-12 conjugated linoleic acids activated endoplasmic reticulum stress and induced apoptosis in HCT116 colon cancer cells, and this was accompanied by increased levels of ROS; these responses were blocked by cotreatment of cells with the antioxidants N -acetyl-L-cysteine and vitamin E [35] . Similarly, the anticancer agent IL-δ inhibited HT-29 colon cancer cell growth and induced apoptosis by increasing caspase 3 activity and the levels of the proapoptotic protein Bax-2, and cotreatment of HT-29 cells with the antioxidant Trolox reversed IL-δ-mediated induction of apoptosis [36] .
In addition to phytochemicals and naturally occurring anticancer agents, several synthetic anticancer drugs induce ROS. Treatment of HCT-116 colon cancer cells with a novel osmiumbased organometallic compound induced autophagy and apoptosis, disrupted the electron transport chain, changed mitochondrial morphology, leading to decreased MMP and ATP levels, and increased ROS levels in these cells. Colon cancer cells that were sensitive to the effects of the osmium-based organometallic compounds such as HCT-116 and RKO cells induced mitochondria-dependent ROS levels, whereas cells that were insensitive to treatment with the osmium-based organometallic compounds such as HT-29 and SW620 cells failed to show any increase in ROS levels, indicating that the ROS-dependent effect of the osmium-based organometallic compounds was cell-context-dependent. In addition, cotreatment of HCT116 cells with the antioxidant N-acetyl-Lcysteine reversed the proapoptotic effects of the osmium-based organometallic compounds on these colon cancer cells [37] . Similarly, a study investigating the antineoplastic effects of a stable mixed phosphine gold(I) complex-[Au(tBu 3 P) (dppet)Cl], where tBu 3 P is tris(tert-butyl)phosphine and dppet is bis(diphenylphosphino)ethene-also demonstrated the role of ROS in mediating its anticarcinogenic effects in colorectal cancer cells. [Au(tBu 3 P)(dppet)Cl] induced apoptosis and increased the percentage of cells in sub-G 1 phase; oligonucleosomal fragmentation, cyctochrome c release from mitochondria, and caspase 3 activation was also observed in HCT-116 colon cancer cells. Induction of apoptosis was due to inhibition of the ROS scavenging enzyme thioredoxin reductase, which is responsible for reducing levels of hydrogen peroxide, which is released into the cell after mitochondrial damage. Treatment of HCT-116 cells with [Au(tBu 3 P)(dppet)Cl] inhibited both cytosolic and mitochondrial isoforms of the enzyme [38] .
Chromate [Cr(VI)] containing compounds are also carcinogenic; however, their mechanisms of action are unclear. However, a recent study in DLD1 colon cancer cells showed that Cr(VI) inhibited cell cycle progression at the S phase, and these effects were blocked by cotreatment with the antioxidant catalase, indicating that the effects of Cr(VI) may be mediated by hydrogen peroxide. In addition, activation of p53 was observed when DLD1 cells were treated with Cr(IV), and cotreatment of cells with small hairpin RNA for p53 blocked S phase cell cycle arrest; these responses were also dependent on induction of ROS [39] .
Sp Transcription Factors as a Target of Drug-Induced ROS
Results from numerous clinical studies and in vitro experiments have shown that even targeted therapies for disrupting growth and survival of cancer cells are complex and not completely understood. Although some mechanismbased drugs show some promise, their beneficial therapeutic efficacy has been limited owing to the complex labyrinth-like signaling pathways and regulatory networks that allow cancer cells to grow and survive. For example, inhibition of individual growth/survival-promoting and angiogenic pathways are not effective since cancer cells can function by relying on alternative pathways; hence, there is a need for therapeutics that can simultaneously target multiple pathways in cancer cells and tumors. To this end, our laboratory has focused on Sp transcription factors since Sp1 and other Sp transcription factors regulate expression of multiple genes that are important for cancer cell growth and survival, and Sp transcription factors can be effectively targeted by various anticancer agents.
Sp Transcription Factors
Members of the Sp/Krüppel-like factor family have a highly conserved DNA binding domain that consists of three contiguously placed C2H2-type zinc fingers that are located at the C-terminal region. Members of the family bind to G C b o x e s ( G G G G C G G G G ) , G T / C A C C C b o x e s (GGTGTGGGG), and basic transcription elements to regulate gene transcription [44] [45] [46] [47] . Evidence from studies conducted in our laboratory and others indicates that Sp transcription factors are overexpressed in several cancer cell lines, including colon, bladder, pancreatic, prostate, breast, thyroid, and esophageal cancer cell lines, and play a crucial role in tumor growth, development, and metastasis [48] [49] [50] [51] [52] [53] . RNA interference studies conducted in pancreatic cancer cells reveals that Sp1, Sp3, and Sp4 are involved in vascular endothelial growth factor (VEGF), VEGF receptor 1 (VEGFR1), and VEGF receptor 2 (VEGFR2) expression, and knockdown of Sp1, Sp3, and Sp4 by RNA interference also affected pancreatic cancer cell growth and cell cycle progression, with a decreased percentage of cells in G 2 /M and S phases and an increased percentage of cells in G 0 /G 1 phase. This was accompanied by increased expression of the cyclin-dependent kinase inhibitor p27 with Sp3 knockdown [54] [55] [56] . Although Sp transcription factors are important for embryonic and postnatal growth and development, expression of Sp1 decreases with age, and in adults there are large differences in expression of Sp transcription factors in tumor tissue (high expression) versus nontumor tissue (low) [53, [57] [58] [59] [60] [61] .
Targeting Sp Transcription Factors
Research in our laboratory has focused on developing anticancer drugs that downregulate Sp1, Sp3, and Sp4 expression and thereby inhibit pathways required for cancer growth, proliferation, survival, angiogenesis, and metastasis. Anticancer agents that decrease expression of Sp transcription factors include compounds such as betulinic acid, curcumin, arsenic trioxide, synthetic triterpenoids and NSAIDs, and these agents decrease expression of key regulators of cell growth (epidermal growth factor receptor, cyclin D1, c-MET), survival (Bcl-2, survivin), inflammation (nuclear factor κB), and angiogenesis (VEGF, VEGFR1, VEGFR2) [50, 51, 54, 62•] . Multiple mechanistic pathways are involved in drug-mediated downregulation of Sp transcription factors, and these mechanisms are dependent on the individual drug and cancer cell line. Several of these agents that downregulate Sp transcription factors act through a transcriptional repression pathway that is activated by ROS.
Role of ROS in Drug-Mediated Dowregulation of Sp Transcription Factors
Studies in our laboratory have shown that several anticancer compounds mediate their effects via induction of oxidative stress and generation of ROS, which is necessary for decreased expression of Sp transcription factors.
Ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094), a novel nitro-NSAID induced ROS and decreased MMP in SW480 and RKO colon cancer cells, and treatment with the antioxidants glutathione (GSH) and dithiothreitol inhibited ROS generation, prevented the loss of MMP, and reversed the effects on downregulation of Sp1, Sp3, and Sp4 and Sp-dependent genes [42•] . Similarly ascorbic acid (vitamin C), which induced hydrogen peroxide, decreased SW480 and RKO colon cancer cell proliferation and induced apoptosis and necrosis, and this was accompanied by downregulation of Sp1, Sp3, and Sp4 and Sp-regulated gene products such as c-MET, epidermal growth factor receptor, cyclin D1, survivin, Bcl-2, VEGF, VEGFR1, and VEGFR2. Moreover these responses and affected genes were inhibited in cells cotreated with the antioxidant GSH [43] . In another study, curcumin and a synthetic analog of curcumin, (3E ,5E )-3,5-bis Role of Zinc Finger and BTB Domain Containing 10 and MiR-27a in ROS-Dependent Drug-Induced Downregulation of Sp Proteins A study investigating the transcriptional regulation of gastrin, a gastrointestinal tract growth factor, discovered that a novel zinc finger and BTB domain containing 10 (ZBTB10/RIN ZF) protein binds to the CACC cis-regulatory elements of the gastrin promoter and interferes with Sp1 binding and transactivation of the gastrin gene, suggesting that ZBTB10 may function as an Sp1 repressor [63] . Subsequent studies showed that after transfection of the 2′-O-methyl RNA antisense miR-27a in SKBr3 breast cancer cells, ZBTB10 mRNA was induced, indicating that miR-27a transcriptionally suppressed the expression of the Sp1 repressor ZBTB10 [64] . Subsequent overexpression studies and experiments using antisense miR-27a in breast cancer cells established that downregulation of the oncogenic microRNA miR-27a was necessary for induction of expression of ZBTB10, which in turn acts as a transcriptional repressor for Sp transcription factors and Sp-regulated genes by competitively binding to GC-rich sites on their promoter sequences. Drugs such as curcumin and GT-094 induce ROS in colon cancer cells, and this is accompanied by decreased miR-27a levels and induction of ZBTB10, which in turn results in downregulation of Sp proteins and Sp-dependent genes. Cotreatment of these cells with antioxidants such as dithiothreitol and GSH blocks induction of ZBTB10 and suppression of miR-27a levels in these cells, indicating that these compounds mediate their effects on Sp proteins and Sp-regulated genes by inducing ROS (Fig. 1) [41•, 42•] . In addition, betulinic acid, a naturally Recent studies investigating the role of human POK family members as transcriptional repressors showed that zinc finger and BTB domain containing 4 (ZBTB4) also binds GC-rich sequences [65] . In addition, the Kaplan-Meier survival analysis of two publicly available breast cancer patient data sets showed that patients with high expression levels of ZBTB4 exhibited increased relapse free-survival compared with patients with low ZBTB4 expression. Analysis of publicly available mRNA and microRNA data sets indicated that ZBTB4 can be negatively regulated by miR-17-5p and miR-20a, which form part of the miR-17-92 cluster. Knocking down miR-20a and overexpression of ZBTB4 in MCF-7 and MDA-MB-231 breast cancer cell lines downregulated expression of Sp proteins and Sp-regulated gene products, indicating that miR-20a and related paralogs enhance expression of Sp proteins by suppressing the Sp repressor ZBTB4 [66••] . Studies conducted in our laboratory show that drugs, including curcumin and RL197, target Sp1, Sp3, and Sp4 and Spdependent genes by inducing ROS, which in turn disrupt the ZBTB4-miR-20a-miR-17-5-p axis in RKO and SW480 colon cancer cells; these effects are blocked by cotreating the cells with GSH, indicating that the anticarcinogenic effects of these drugs are ROS-dependent (Fig. 1) [41•] . Although the mechanisms of ROS-dependent downregulation of miR-27a and miR-20a (paralogs) are unknown, it is possible that transacting factors are modulated through genome-wide chromatin shifts, as recently reported for hydrogen peroxide in SW480 colon cancer cells [67••] .
Conclusions
Anticancer agents that induce ROS have long been recognized as an important class of drugs that inhibit cancer cell proliferation and survival, and this has been attributed, in part, to either direct or indirect effects on mitochondria. However, the discovery that ROS also disrupts microRNA-ZBTB4/ ZBTB10 interactions (Fig. 1) , which leads to downregulation of Sp transcription factors and Sp-regulated genes, now defines an important new ROS-mediated pathway that explains the efficacy of ROS inducers, and this will facilitate their development for combination therapies with other anticancer agents.
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